Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
5.5
4.8
Journals
Antibiotics
Special Issues
Rational Use of Antimicrobials for Bloodstream Infections
share announcement

Rational Use of Antimicrobials for Bloodstream Infections

A special issue of Antibiotics (ISSN 2079-6382). This special issue belongs to the section "Antibiotic Therapy in Infectious Diseases".

Deadline for manuscript submissions: closed (28 February 2023) | Viewed by 1929

Special Issue Editors

Dr. Ching-Chi Lee

E-Mail Website
Guest Editor
Clinical Medicine Research Center, National Cheng Kung University Hospital, No. 138, Sheng Li Road, Tainan 70403, Taiwan
Interests: bloodstream infections; antimicrobial stewardship program; empirical antimicrobial therapy; sepsis
Special Issues, Collections and Topics in MDPI journals
Dr. Yuan-Pin Hung

E-Mail Website
Guest Editor
Department of Internal Medicine, Tainan Hospital, Ministry of Health and Welfare, Tainan, Taiwan
Interests: bacteremia; bloodstream infection; antimicrobial stewardship program; empirical; definitive; antibiotic
Special Issues, Collections and Topics in MDPI journals
Dr. Chih-Chia Hsieh

E-Mail Website
Guest Editor
Department of Emergency Medicine, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, Tainan, Taiwan
Interests: bacteremia; bloodstream infection; antimicrobial stewardship program; empirical; definitive; antibiotic

Special Issue Information

Dear Colleagues,

Bloodstream infection (BSI) is a common infectious disease associated with substantial morbidity and mortality worldwide. While a positive blood culture is mandatory for establishment of the presence of the BSI, there are numerous determinants that must be considered for clinicians. Hence, there is a pressing need to study and develop new diagnoses and therapeutic strategies (such as the antimicrobial stewardship program (ASP)) for BSIs. The aim of the current Special Issue is to collect, update, and harmonize the most recent literature detailing the prognostic and/ or economic effect of ASP on patients experiencing BSIs. Additionally, we aim to touch herein the updated aspects of the BSI treatment, spanning from the efficacies of prompt empirical and definitive therapy to the latest advancements in antimicrobial discovery.

As the Guest Editor of a Special Issue of Antibiotics focused on antimicrobial therapy for BSIs, I invite you, as an expert in this field, to submit a manuscript for publication, in terms of original research, review articles, or short communications that report on recent progress to further expand the knowledge of antimicrobial therapy

Dr. Ching-Chi Lee
Dr. Yuan-Pin Hung
Dr. Chih-Chia Hsieh
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Antibiotics is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • bacteremia
  • bloodstream infection
  • antimicrobial stewardship program
  • empirical
  • definitive
  • antibiotic

Published Papers (1 paper)

Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Other

10 pages, 544 KiB  
Brief Report
Antimicrobial Therapy Duration for Bloodstream Infections Caused by Pseudomonas aeruginosa or Acinetobacter baumannii-calcoaceticus complex: A Retrospective Cohort Study
by Rodrigo Douglas Rodrigues, Rebeca Carvalho Lacerda Garcia, Gabriel Almeida Bittencourt, Vicente Bouchet Waichel, Ester Carvalho Lacerda Garcia and Maria Helena Rigatto
Antibiotics 2023, 12(3), 538; https://doi.org/10.3390/antibiotics12030538 - 8 Mar 2023
Cited by 2 | Viewed by 1692
Abstract
Background: Ideal therapy duration for Pseudomonas aeruginosa or Acinetobacter baumannii-calcoaceticus complex (ABC) bloodstream infections (BSI) is not defined, especially in the context of carbapenem resistance. In this study, we compared short- (≤7 days) and long-term (>7 days) antimicrobial therapy duration for these infections. [...] Read more.
Background: Ideal therapy duration for Pseudomonas aeruginosa or Acinetobacter baumannii-calcoaceticus complex (ABC) bloodstream infections (BSI) is not defined, especially in the context of carbapenem resistance. In this study, we compared short- (≤7 days) and long-term (>7 days) antimicrobial therapy duration for these infections. Methods: We performed a retrospective cohort study in two tertiary-care hospitals in Porto Alegre, Brazil, from 2013 to 2019. Eligible patients aged ≥18 years were included and excluded for the following criteria: polymicrobial infections, treatment with non-susceptible antibiotics, complicated infections, or early mortality (<8 days of active antimicrobial therapy). The 30-day mortality risk was evaluated using a Cox regression model. Results: We included 237 BSI episodes, 51.5% caused by ABC and 48.5% by Pseudomonas aeruginosa. Short-term therapy was not associated with 30-day mortality, adjusted hazard ratio 1.01, 95% confidence interval 0.47–2.20, p = 0.98, when adjusted for Pitt score (p = 0.02), Charlson Comorbidity Index score (p < 0.01), and carbapenem resistance (p < 0.01). Among patients who survived, short-term therapy was associated with shorter hospital stay (p < 0.01). Results were maintained in the subgroups of BSI caused by carbapenem-resistant bacteria (p = 0.76), ABC (p = 0.61), and Pseudomonas aeruginosa (p = 0.39). Conclusions: Long-term therapies for non-complicated Pseudomonas aeruginosa and ABC BSI were not superior to short-term therapy for 30-day mortality. Full article
(This article belongs to the Special Issue Rational Use of Antimicrobials for Bloodstream Infections)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-1
Back to TopTop